Registry of Patients with Enterobacterales and Pseudomonas aeruginosa Infections Exhibiting a Ceftazidime/Avibactam Resistance Profile (RESIST-CA

It is necessary to conduct a joint identification effort with Méderi’s Microbiology Department to detect isolates from patients with enterobacterial and Pseudomonas aeruginosa infections resistant to ceftazidime/avibactam mediated by enzyme co-production.
Accordingly, the Infectious Diseases team, the Antimicrobial Optimization Program (PROA), and the Microbiology Department will launch a health registry to identify patients presenting this form of bacterial resistance.

To implement the Institutional Registry of patients with infections caused by Enterobacterales and Pseudomonas aeruginosa exhibiting a ceftazidime/avibactam resistance profile—mediated by KPC gene mutation or enzyme co-production (RESIST-CA)—treated in the inpatient wards and intensive care units of Hospital Universitario Mayor–Méderi beginning January 1, 2023.

This registry aims to collect epidemiological data and clinical outcomes of patients, as well as to generate knowledge by developing research protocols based on the data obtained. It will enable us to understand the behavior of these resistance mechanisms within the institution, assess clinical outcomes, and explore additional insights.